Weiss Multi Strategy Advisers LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 3.4% during the first quarter, Holdings Channel reports. The firm owned 31,086 shares of the biopharmaceutical company’s stock after buying an additional 1,010 shares during the period. Weiss Multi Strategy Advisers LLC’s holdings in Celgene Corporation were worth $3,868,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in Celgene Corporation by 149.8% in the first quarter. Bank of Montreal Can now owns 3,299,988 shares of the biopharmaceutical company’s stock valued at $410,615,000 after buying an additional 1,979,061 shares during the period. Investec Asset Management LTD bought a new stake in Celgene Corporation during the first quarter valued at approximately $194,490,000. Pioneer Investment Management Inc. increased its stake in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares during the period. Swiss National Bank increased its stake in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after buying an additional 588,000 shares during the period. Finally, Smith Asset Management Group LP bought a new stake in Celgene Corporation during the first quarter valued at approximately $71,276,000. 78.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.41% during trading on Friday, reaching $130.90. The company had a trading volume of 1,017,230 shares. The company has a market capitalization of $102.41 billion, a PE ratio of 40.54 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The stock’s 50-day moving average price is $134.23 and its 200-day moving average price is $124.17.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. On average, equities analysts expect that Celgene Corporation will post $7.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/weiss-multi-strategy-advisers-llc-has-3-87-million-stake-in-celgene-corporation-nasdaqcelg/1475423.html.

CELG has been the topic of several analyst reports. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $98.00 price target (up from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Monday, May 22nd. One analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene Corporation has a consensus rating of “Buy” and a consensus target price of $147.00.

In other news, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 over the last 90 days. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.